Orphazyme20.jpg

Outlook

OUTLOOK

OUTLOOK

For the full-year 2023 the Company anticipates an operating loss in the range of DKK 30 – 35 million. The Company expects to end 2023 with DKK 6 - 10 million in cash.

There are inherent risks and uncertainties in our Outlook for 2023 including the limited nature of our business activities, the final outcome of the class action lawsuit in the United States and our future prospects.